Evidence map›Paper›PMID 34125317›Full record

ReviewMolecular and cellular biochemistry2021

Myocardial remote ischemic preconditioning: from cell biology to clinical application.

Martín Donato, Eliana P Bin, Verónica D Annunzio, Ricardo J Gelpi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular and cellular biochemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Molecular Research on Heart Protection.International journal of molecular sciences · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Martín Donato *Department of Pathology, Faculty of Medicine, Institute of Cardiovascular Pathophysiology (INFICA), University of Buenos Aires, 950 J. E. Uriburu, 2nd floor, C1114AAD, Buenos Aires, Argentina.
Eliana P BinDepartment of Pathology, Faculty of Medicine, Institute of Cardiovascular Pathophysiology (INFICA), University of Buenos Aires, 950 J. E. Uriburu, 2nd floor, C1114AAD, Buenos Aires, Argentina.
Verónica D AnnunzioDepartment of Pathology, Faculty of Medicine, Institute of Cardiovascular Pathophysiology (INFICA), University of Buenos Aires, 950 J. E. Uriburu, 2nd floor, C1114AAD, Buenos Aires, Argentina.
Ricardo J Gelpi *Department of Pathology, Faculty of Medicine, Institute of Cardiovascular Pathophysiology (INFICA), University of Buenos Aires, 950 J. E. Uriburu, 2nd floor, C1114AAD, Buenos Aires, Argentina. rgelpi@fmed.uba.ar.ORCID http://orcid.org/0000-0001-6491-9209

Funding

Agencia Nacional de Promoción Científica y Tecnológica PICT 01071Secretaria de Ciencia y Tecnica, Universidad de Buenos Aires (AR) UBACYT M032
6 · The paper itself

Abstract

Remote ischemic preconditioning (rIPC) is a cardioprotective phenomenon where brief periods of ischemia followed by reperfusion of one organ/tissue can confer subsequent protection against ischemia/reperfusion injury in other organs, such as the heart. It involves activation of humoral, neural or systemic communication pathways inducing different intracellular signals in the heart. The main purpose of this review is to summarize the possible mechanisms involved in the rIPC cardioprotection, and to describe recent clinical trials to establish the efficacy of these strategies in cardioprotection from lethal ischemia/reperfusion injury. In this sense, certain factors weaken the subcellular mechanisms of rIPC in patients, such as age, comorbidities, medication, and anesthetic protocol, which could explain the heterogeneity of results in some clinical trials. For these reasons, further studies, carefully designed, are necessary to develop a clearer understanding of the pathways and mechanism of early and late rIPC. An understanding of the pathways is important for translation to patients.

Indexed as

Ischemic PreconditioningMyocardial Reperfusion InjuryMyocardiumMyocytes, CardiacAnimalsHumansCardioprotectionMyocardial infarctionRemote ischemic preconditioning

Identifiers

PMID34125317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.